Division of Infectious Diseases, Department of Medicine, Louisiana State University Health Sciences Center, Shreveport, LA, USA.
Department of Pharmacy, Ochsner LSU Health Shreveport, Shreveport, LA, USA.
Infection. 2022 Aug;50(4):1007-1012. doi: 10.1007/s15010-022-01805-y. Epub 2022 Mar 24.
Cryptococcal infection has been increasingly reported in patients with COVID-19 infection, but the epidemiological factors, presentation, diagnostic certainty, and outcome have not been well-described.
We reviewed the published cases of COVID-19-associated Cryptococcus infections (CACI) to shed the light on the burden of this infection.
We identified 13 patients with confirmed cryptococcal infection. Cryptococcus infection was primarily seen in patients with severe COVID-19 disease who received corticosteroids therapy and admitted to the intensive care unit. Pulmonary CACI was the most common reported infection followed by cryptococcal meningitis.
In light of the high mortality rate, clinicians should maintain a high clinical suspicion of CACI in critically ill patients.
COVID-19 感染患者中越来越多地报告了隐球菌感染，但该病的流行病学因素、表现、诊断确定性和结局尚未得到很好描述。
我们回顾了已发表的 COVID-19 相关隐球菌感染（CACI）病例，以了解该病的负担。
我们共确定了 13 例确诊的隐球菌感染患者。隐球菌感染主要见于接受皮质类固醇治疗并入住重症监护病房的重症 COVID-19 患者。肺部 CACI 是最常见的报道感染，其次是隐球菌性脑膜炎。
鉴于高死亡率，临床医生应在重症患者中对 CACI 保持高度临床怀疑。
